Mindray Medical REITERATED at Outperform and 2 Must-See Reiterated Ratings

Wall St. Watchdog reveals information about companies for which stock analysts reiterated their ratings on August 20th.

ANN (NYSE:ANN): UBS reiterated its rating of Buy for this company and changed its price target from $33 to $40. FBR Capital reiterated its rating of Outperform for this company and changed its price target from $33 to $35.

Don’t Miss: Apple Getting SLAMMED, But Shares SOAR.

HollyFrontier (HFC): Oppenheimer reiterated its rating of Outperform for this company and changed its price target from $40 to $46.

Mindray Medical (NYSE:MR): Oppenheimer reiterated its rating of Outperform for this company and changed its price target from $34 to $39.

Don’t Miss: The Week Ahead: Fed’s Minutes, Existing Home Sales, and H-P’s Earnings.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.